SCHEMBL1285185

SCHEMBL1285185

CCOC(=O)c1cnc2cc(C(C)C)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.59
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
P2RY12 Q9H244 1/20 0.46
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
HPGDS O60760 4/20 0.44
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KMT2A Q03164 2/20 0.42
CASP3 P42574 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10465995 0.85 MAOB (0.65) MAOBPDGFRBPDGFRANPC1RAB9A
SCHEMBL8001650 0.83 MAOB (0.71) MAOBPDGFRBPDGFRANPC1RAB9A
SCHEMBL2202317 0.82 MAOB (0.66) MAOBPDGFRBPDGFRANPC1RAB9A
SCHEMBL5647010 0.81 MAOB (0.61) MAOBPDGFRBPDGFRANPC1RAB9A
SCHEMBL4538765 0.81 MAOB (0.61) MAOBPDGFRBPDGFRANPC1RAB9A
SCHEMBL17447286 0.81 MAOB (0.61) MAOBPDGFRBPDGFRANPC1RAB9A
SCHEMBL4156881 0.81 MAOB (0.61) MAOBPDGFRBPDGFRANPC1RAB9A
SCHEMBL2204650 0.81 MAOB (0.65) MAOBPDGFRBPDGFRAP2RY12NPC1
SCHEMBL15701606 0.80 CA12 (0.53) NPC1RAB9AMEN1ALDH1A1KMT2A
SCHEMBL1645224 0.80 MGAM (0.57) HPGDSSMN1; SMN2OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
WO-2007133637-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 MAOB 3327/4885PDGFRB 1019/4885PDGFRA 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.